Horizon Selected for Final of World Entrepreneurship Competition

29 May 2009

On June 18th the winner of this year’s Global Entrepreneurship Competition, held in Barcelona, will be announced. Horizon Discovery, based in Cambridge England has been selected as a finalist and one of 26 companies located across the globe capable of highest future growth potential.

HIT-Barcelona’09 is an international summit bringing together CEOs, directors of innovation, entrepreneurs and investors from around the world in Barcelona from June 17 to 19, 2009. Entries for the competition have been selected from among the best entrepreneurial projects by representatives from top Entrepreneurship Centers (Business Schools, Incubators, Technology Parks, Universities, Angel Investor Networks, etc.) from around the world. Horizon is one of only two short-listed UK companies.

Horizon Discovery, which began commercial operation in July 2007 is fast becoming a world leader in the supply of tools and services to the pharmaceutical industry that enable the discovery of new cancer therapies targeted at genetically‐defined patient populations. The company is part of University of Cambridge’s commercialisation office, Cambridge Enterprise Limited, portfolio of investment companies and was nominated by Cambridge’s Judge Institute for Management Studies as one of five leading early-stage companies from the Cambridge region.

Horizon’s award winning (UK Medical Futures Innovation in Cancer 2008) GENESIS™ technology is a gene engineering platform that uses a proprietary viral DNA construct with a vastly improved ability to target any pre‐determined endogenous gene location in human cells grown in culture. The result is a means of generating accurate and stable functional models of complex disease states that can be readily deployed in existing drug discovery and development programmes.

The company has developed a portfolio of 150+ products and is building license, service and collaborative relationships with the world’s leading pharmaceutical companies including Genentech, Novartis, Millennium and OSI Pharmaceuticals who recognise that the traditional approach of ‘one‐size‐fits‐all’ approach in search of new cancer drugs is no longer sufficient. Horizon’s tools and services provide a better way for researchers to develop drugs which will provide individual patient care.